Light-sensitive ion-passing molecules

US9359449B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9359449-B2
Application numberUS-201213623612-A
CountryUS
Kind codeB2
Filing dateSep 20, 2012
Priority dateMar 17, 2010
Publication dateJun 7, 2016
Grant dateJun 7, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The invention provides polynucleotides and methods for expressing light-activated proteins in animal cells and altering an action potential of the cells by optical stimulation. The invention also provides animal cells and non-human animals comprising cells expressing the light-activated proteins.

First claim

Opening claim text (preview).

What is claimed is: 1. A method of identifying transsynaptic connection between neuronal cells in an animal or a tissue, comprising: a) administering a first viral vector encoding a Cre recombinase fused to a transcellular tracer protein to neuronal cells in region A of the animal or tissue, wherein the transcellular tracer protein is wheat germ agglutinin (WGA) or tetanus toxin-fragment C (TTC), wherein the first viral vector is selected from the group consisting of an adenoassociated virus vector, a herpes simplex virus vector, and a lentiviral vector; b) administering a second viral vector encoding a light-activated protein to neuronal cells in region B of the animal or tissue, wherein the expression of the light-activated protein depends on the presence of the Cre recombinase, wherein the light-activated protein comprises an amino acid sequence at least 95% identical to the sequence shown in SEQ ID NO:3, SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:4, wherein the second viral vector is selected from the group consisting of an adenoassociated virus vector, a herpes simplex virus vector, and a lentiviral vector; and c) identifying neuronal cells expressing the light-activated protein in region B, wherein the expression of the light-activated protein in the neuronal cells indicates that these cells are in transsynaptic connection with the cells in region A. 2. The method of claim 1 , wherein the first viral vector and the second viral vector are lentiviral vectors. 3. The method of claim 1 , wherein the transcellular tracer protein is wheat germ agglutinin (WGA). 4. The method of claim 1 , wherein the light-activated protein comprises an amino acid sequence at least 95% identical to the sequence shown in SEQ ID NO:3. 5. A method of generating optical control of targeted neuronal cells in an animal or tissue, comprising: a) administering a first viral vector expressing a Cre recombinase fused to a transcellular tracer protein to region A of the animal or tissue, wherein the transcellular tracer protein is wheat germ agglutinin (WGA) or tetanus toxin-fragment C (TTC), wherein the first viral vector is selected from the group consisting of an adenoassociated virus vector, a herpes simplex virus vector, and a lentiviral vector; b) administering a second viral vector encoding a light-activated protein to region B of the animal or tissue, wherein the expression of the light-activated protein depends on the presence of the Cre recombinase, wherein the neuronal cells in region A and in region B are in transsynaptic connection, and wherein the light-activated protein comprises an amino acid sequence at least 95% identical to the sequence shown in SEQ ID NO:3, SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:4, wherein the second viral vector is selected from the group consisting of an adenoassociated virus vector, a herpes simplex virus vector, and a lentiviral vector; and c) controlling action potential of a neuronal cell in region B with light that activates the light-activated protein. 6. The method of claim 5 , wherein the first and the second viral vectors are lentiviral vectors. 7. The method of claim 5 , wherein the transcellular tracer protein is wheat germ agglutinin (WGA). 8. The method of claim 5 , wherein the light-activated protein comprises an amino acid sequence at least 95% identical to the sequence shown in SEQ ID NO:3. 9. A method of controlling action potential of a neuron in an animal, comprising activating a light-activated protein in the neuron with light to generate action potential change, wherein expression of the light-activated protein in the neuron is generated by: a) administering a first viral vector expressing a Cre recombinase fused to a transcellular tracer protein to region A of the animal, wherein the transcellular tracer protein is wheat germ agglutinin (WGA) or tetanus toxin-fragment C (TTC), wherein the first viral vector is selected from the group consisting of an adenoassociated virus vector, a herpes simplex virus vector, and a lentiviral vector; and b) administering a second viral vector encoding a light-activated protein to region B of the animal which contains the neuron, wherein the expression of the light-activated protein depends on the presence of the Cre recombinase, wherein the neurons in region A and region B are in transsynaptic connection, wherein the light-activated protein comprises an amino acid sequence at least 95% identical to the sequence shown in SEQ ID NO:3, SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:4, wherein the second viral vector is selected from the group consisting of an adenoassociated virus vector, a herpes simplex virus vector, and a lentiviral vector. 10. The method of claim 9 , wherein the first viral vector and the second viral vector are lentiviral vectors. 11. The method of claim 9 , wherein the transcellular tracer protein is wheat germ agglutinin (WGA). 12. The method of claim 9 , wherein the light-activated protein comprises an amino acid sequence at least 95% identical to the sequence shown in SEQ ID NO:3. 13. The method of claim 1 , wherein the transcellular tracer protein is TTC. 14. The method of claim 1 , wherein the light-activated protein comprises: a) a core amino acid sequence at least 95% identical to the sequence shown in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, or SEQ ID NO:4; and b) an endoplasmic reticulum (ER) export signal. 15. The method of claim 14 , wherein the ER export signal comprises the amino acid sequence FCEYENEV (SEQ ID NO:12). 16. The method of claim 14 , where the light-activated protein comprises a membrane trafficking signal. 17. The method of claim 16 , wherein the membrane trafficking signal comprises the amino acid sequence KSRITSEGEYIPLDQIDINV (SEQ ID NO:11). 18. The method of claim 5 , wherein the transcellular tracer protein is TTC. 19. The method of claim 5 , wherein the light-activated protein comprises: a) a core amino acid sequence at least 95% identical to the sequence shown in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, or SEQ ID NO:4; and b) an endoplasmic reticulum (ER) export signal. 20. The method of claim 19 , wherein the ER export signal comprises the amino acid sequence FCEYENEV (SEQ ID NO:12). 21. The method of claim 19 , where the light-activated protein comprises a membrane trafficking signal. 22. The method of claim 16 , wherein the membrane trafficking signal comprises the amino acid sequence KSRITSEGEYIPLDQIDINV (SEQ ID NO:11). 23. The method of claim 9 , wherein the transcellular tracer protein is TTC. 24. The method of claim 9 , wherein the light-activated protein comprises: a) a core amino acid sequence at least 95% identical to the sequence shown in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, or SEQ ID NO:4; and b) an endoplasmic reticulum (ER) export signal. 25. The method of claim 24 , wherein the ER export signal comprises the amino acid sequence FCEYENEV (SEQ ID NO:12). 26. The method of claim 24 , where the light-activated protein comprises a membrane trafficking signal. 27. The method of claim 26 , wherein the membrane trafficking signal comprises the amino acid sequence KSRITSEGEYIPLDQIDINV (SEQ ID NO:11).

Assignees

Inventors

Classifications

  • viral genome or elements thereof as genetic vector · CPC title

  • Animal model comprising a reporter system for screening tests · CPC title

  • where the vector is derived from a parvovirus · CPC title

  • C07K14/405Primary

    from algae · CPC title

  • containing a signal sequence · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9359449B2 cover?
The invention provides polynucleotides and methods for expressing light-activated proteins in animal cells and altering an action potential of the cells by optical stimulation. The invention also provides animal cells and non-human animals comprising cells expressing the light-activated proteins.
Who is the assignee on this patent?
Univ Leland Stanford Junior
What technology area does this patent fall under?
Primary CPC classification C07K14/405. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Jun 07 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).